Sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, reduces all-cause mortality
and the rate of heart failure hospitalizations in patients with heart failure with reduced …

Background Major classes of medical therapy for heart failure with reduced ejection fraction
(HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan …

Background Compared to angiotensin inhibition, angiotensin-neprilysin “blockade”
improves mortality and reduces hospitalizations in patients with heart failure (HF) with …

Background: Sacubitril/Valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). The …

Sacubitril/valsartan has become an important first-line drug for symptomatic heart failure
(HF) patients, especially with left ventricular (LV) ejection fraction (LVEF)< 50%. However …

Aims The angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan (LCZ696)
is recommended for the treatment of patients with heart failure in New York Heart …

Background In patients with heart failure with reduced ejection fraction (HFrEF), treatment
with sacubitril–valsartan (S/V) may reverse left ventricular remodeling (rLVR). Whether this …

Background Doses of sacubitril/valsartan (Sac/Val) achieved in clinical trials of heart failure
with reduced ejection fraction (HFrEF) are often not reached in clinical practice. Objectives …

Background The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan is known to
improve outcomes of cardiac death and hospitalization due to heart failure in patients with …

Aims The study aims to explore the real‐world titration patterns of sacubitril/valsartan in a
chronic heart failure (HF) follow‐up management system and the effect on the recovery of …